Dossier
Relacorilant
Coverage of Relacorilant in the Nexus archive.
- Repurposed drug may extend survival in aggressive ovarian cancer, trial shows
A drug originally used to treat Cushing’s syndrome, Relacorilant, showed potential in extending survival for patients with platinum-resistant ovarian cancer in a clinical trial. The study suggests repurposing the medication could improve outcomes for aggressive ovarian cancer cases that resist standard platinum-based chemotherapy.